Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxorubicin nanoparticles - Valerio Therapeutics

Next Previous
X
Search
Drug Profile

Doxorubicin nanoparticles - Valerio Therapeutics

Alternative Names: BA-003; Doxorubicin Transdrug; Doxorubicin-Transdrug; Livatag

Latest Information Update: 08 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioAlliance Pharma
  • Developer CNRS; Onxeo SA
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Liver cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 26 Oct 2017 Discontinued - Clinical-Phase-Unknown for liver cancer (Combination therapy, First-line therapy) (IV)
  • 26 Oct 2017 Discontinued - Phase-II/III for liver cancer in European Union (Intra-arterial)
  • 26 Oct 2017 Discontinued - Phase-III for liver cancer (Late-stage disease, Second-line therapy or greater) in Saudi Arabia, Turkey, Spain, Lebanon, Italy, Hungary, Germany, France, Egypt, Belgium, Austria, USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top